NervGen Strengthens Board Leadership to Accelerate Clinical and Corporate Growth
NervGen Pharma (OTCQB: NGENF), a clinical-stage biotech company focused on neurological treatments, announced key leadership changes to its Board of Directors. Dr. Adam Rogers, representing the company's largest shareholder, has been unanimously appointed as the new Board Chair, succeeding Glenn Ives who resigned after four years of service.
The leadership transition comes at a strategic time following positive topline results from the chronic cohort of the Phase 1b/2a CONNECT SCI Study for NVG-291, the company's neuroreparative therapy candidate. Dr. Rogers, who previously served as NervGen's interim president, brings significant expertise as a board-certified physician and biotech entrepreneur, having co-founded Hemera Biosciences and developed HMR59, now in clinical trials as JNJ-1887.
NervGen Pharma (OTCQB: NGENF), una societ脿 biotecnologica in fase clinica specializzata in trattamenti neurologici, ha annunciato importanti cambiamenti nella sua Direzione. Il dottor Adam Rogers, rappresentante del maggiore azionista della societ脿, 猫 stato nominato all'unanimit脿 nuovo Presidente del Consiglio di Amministrazione, succedendo a Glenn Ives, che si 猫 dimesso dopo quattro anni di servizio.
Il passaggio di leadership avviene in un momento strategico, a seguito dei risultati positivi preliminari del gruppo cronico dello studio di Fase 1b/2a CONNECT SCI per NVG-291, il candidato terapeutico neuro-riparatore dell'azienda. Il dottor Rogers, che in precedenza ha ricoperto il ruolo di presidente ad interim di NervGen, porta con s茅 una significativa esperienza come medico certificato e imprenditore biotecnologico, avendo co-fondato Hemera Biosciences e sviluppato HMR59, attualmente in sperimentazioni cliniche come JNJ-1887.
NervGen Pharma (OTCQB: NGENF), una empresa biotecnol贸gica en fase cl铆nica centrada en tratamientos neurol贸gicos, anunci贸 cambios clave en su Junta Directiva. El Dr. Adam Rogers, representante del mayor accionista de la compa帽铆a, fue nombrado por unanimidad como el nuevo presidente de la Junta, reemplazando a Glenn Ives, quien renunci贸 tras cuatro a帽os de servicio.
La transici贸n en el liderazgo llega en un momento estrat茅gico tras los resultados positivos preliminares del cohorte cr贸nico del estudio CONNECT SCI de Fase 1b/2a para NVG-291, el candidato terap茅utico neuroreparador de la empresa. El Dr. Rogers, quien previamente fue presidente interino de NervGen, aporta una gran experiencia como m茅dico certificado y empresario biotecnol贸gico, habiendo cofundado Hemera Biosciences y desarrollado HMR59, actualmente en ensayos cl铆nicos como JNJ-1887.
NervGen Pharma (OTCQB: NGENF)電� 鞁犼步頃欖爜 旃橂鞐� 欷戩爯鞚� 霊� 鞛勳儊 雼硠 氚旍澊鞓ろ厡韥� 須岇偓搿�, 鞚挫偓須岇棎 欤检殧 毽崝鞁� 氤�頇旊ゼ 氚滍憸頄堨姷雼堧嫟. 須岇偓 斓滊寑 欤检＜毳� 雽�響滍晿電� 鞎勲嫶 搿滌爛鞀� 氚曥偓臧� 毵岇灔鞚检箻搿� 靸堧鞖� 鞚挫偓須� 鞚橃灔鞙茧 靹犾瀯霅橃棃鞙茧┌, 4雲勱皠 鞛瀯頃� 旮�霠� 鞎勳澊敫岇姢臧� 靷瀯頄堨姷雼堧嫟.
鞚措矆 毽崝鞁� 甑愳泊電� NVG-291鞚� 毵岇劚 旖旐樃韸� 雽�靸� 1b/2a靸� CONNECT SCI 鞐瓣惮鞚� 旮嶌爼鞝侅澑 齑堦赴 瓴瓣臣 氚滍憸 歆來泟鞐� 鞚措（鞏挫鞀惦媹雼�. 搿滌爛鞀� 氚曥偓電� 鞚挫爠鞐� NervGen 鞛勳嫓 雽�響滊ゼ 鞐瀯頄堨溂氅�, 鞚挫偓須� 瓿奠澑 鞚橃偓鞚挫瀽 氚旍澊鞓ろ厡韥� 旮办梾臧�搿滌劀 Hemera Biosciences毳� 瓿惦彊 靹る頃橁碃 順勳灛 鞛勳儊鞁滍棙 欷戩澑 JNJ-1887(HMR59)鞚� 臧滊皽頃� 瓴巾棙鞚� 氤挫湢頃橁碃 鞛堨姷雼堧嫟.
NervGen Pharma (OTCQB : NGENF), une soci茅t茅 biotechnologique en phase clinique sp茅cialis茅e dans les traitements neurologiques, a annonc茅 des changements importants au sein de son conseil d'administration. Le Dr Adam Rogers, repr茅sentant le principal actionnaire de la soci茅t茅, a 茅t茅 nomm茅 脿 l'unanimit茅 nouveau pr茅sident du conseil, succ茅dant 脿 Glenn Ives, qui a d茅missionn茅 apr猫s quatre ans de service.
Cette transition de leadership intervient 脿 un moment strat茅gique, suite aux r茅sultats positifs pr茅liminaires de la cohorte chronique de l'茅tude CONNECT SCI de phase 1b/2a pour NVG-291, le candidat th茅rapeutique neuro-r茅parateur de la soci茅t茅. Le Dr Rogers, qui a pr茅c茅demment assur茅 la pr茅sidence par int茅rim de NervGen, apporte une expertise significative en tant que m茅decin certifi茅 et entrepreneur en biotechnologie, ayant cofond茅 Hemera Biosciences et d茅velopp茅 HMR59, actuellement en essais cliniques sous le nom de JNJ-1887.
NervGen Pharma (OTCQB: NGENF), ein biotechnologisches Unternehmen in der klinischen Phase mit Fokus auf neurologische Behandlungen, gab wichtige F眉hrungswechsel in seinem Vorstand bekannt. Dr. Adam Rogers, der den gr枚脽ten Anteilseigner des Unternehmens vertritt, wurde einstimmig zum neuen Vorstandsvorsitzenden ernannt und folgt auf Glenn Ives, der nach vier Jahren im Amt zur眉ckgetreten ist.
Der F眉hrungswechsel erfolgt zu einem strategischen Zeitpunkt, nachdem positive Zwischenergebnisse der chronischen Kohorte der Phase-1b/2a CONNECT SCI-Studie f眉r NVG-291, den neuroregenerativen Therapie-Kandidaten des Unternehmens, vorliegen. Dr. Rogers, der zuvor als Interimspr盲sident von NervGen t盲tig war, bringt umfangreiche Erfahrung als zertifizierter Arzt und Biotech-Unternehmer mit, da er Hemera Biosciences mitbegr眉ndet und HMR59 entwickelt hat, das sich derzeit in klinischen Studien unter dem Namen JNJ-1887 befindet.
- None.
- None.
- Dr. Adam Rogers appointed chair as company advances toward key milestones following positive topline chronic cohort results of Phase 1b/2a CONNECT SCI Study
Vancouver, British Columbia--(Newsfile Corp. - July 3, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative treatments for spinal cord injury (SCI) and other neurological conditions, today announced changes to its board of directors to support the next phase of growth and further align corporate strategy with the priorities of its shareholders and the SCI community.
Glenn Ives has resigned from NervGen's Board of Directors. The Board and management thank Glenn for his invaluable contributions and leadership over the past four years. "It has been a privilege to serve as a director and chair during such a pivotal period for NervGen," said Mr. Ives. "With positive topline data from our CONNECT SCI Study now in hand, and the complete dataset expected soon, I am confident that NervGen is on a strong path forward to fulfilling its mission of transforming the lives of individuals living with SCI."
The Board of Directors unanimously appointed Dr. Adam Rogers, a current director and representative of NervGen's largest shareholder, as the new chair. "NervGen is at a pivotal juncture, with positive topline data from our CONNECT SCI Study reinforcing the potential of NVG-291 as both a first-in-class and best-in-class neuroreparative therapy," said Dr. Rogers. "We are actively analyzing and preparing the complete dataset from the chronic cohort, and we're excited to build on NervGen's regulatory and corporate initiatives."
Dr. Rogers is a board-certified physician, biotech entrepreneur, and CEO with extensive experience in clinical and regulatory development. He currently serves as Managing Director of PFP Biosciences, an investment firm focused on breakthrough life sciences technologies, and has been a director at NervGen since 2022. He also served as NervGen's interim president from September 2022 to April 2023. Previously, Dr. Rogers co-founded and served as CEO of Hemera Biosciences, leading the development of HMR59 (now JNJ-1887), an intraocular gene therapy currently in clinical trials for advanced dry age-related macular degeneration. Dr. Rogers holds an M.D. and B.A. from Emory University.
About NVG-291
NervGen holds exclusive worldwide rights to NVG-291, a first-in-class therapeutic peptide targeting nervous system repair. NVG-291's technology is licensed from Case Western Reserve University and is based on academic studies that demonstrated the preclinical efficacy of NVG-291-R, the rodent prototype of NVG-291, in animal models of spinal cord injury. These studies implicated several potential molecular and cellular mechanisms by which NVG-291-R promotes neurorepair and functional improvement in both central and peripheral nervous system injury models. The implicated mechanisms include the promotion of neuronal sprouting, or plasticity, remyelination, and promotion of a non-inflammatory phenotype in the microglial cells. NervGen has received Fast Track designation from the FDA and Orphan Designation from the EMA for NVG-291 in individuals with spinal cord injury.
About NervGen
NervGen (TSXV: NGEN) (OTCQB: NGENF) is a clinical-stage biotech company dedicated to developing innovative treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company is testing the clinical efficacy of its lead candidate, NVG-291, in the Phase 1b/2a CONNECT SCI Study clinical trial in spinal cord injury. (1-10 years post-injury) of this trial showed that NVG-291 met its primary endpoint and demonstrated strong trends in a secondary endpoint assessing hand function. Complete analysis of the chronic cohort is ongoing. Enrollment in the subacute cohort (20-90 days post-injury) of the trial continues, and more information about participation in the subacute study is available at . In addition, the company has initiated preclinical test of concept evaluation of its pipeline candidate, NVG-300, in models of ischemic stroke and spinal cord injury. For more information about NervGen, visit and follow NervGen on and for the latest news on the company.
Contacts
Huitt Tracey, Investor Relations
[email protected]
604.537.2094
Bill Adams, Chief Financial Officer
[email protected]
778.731.1711
Christy Curran
Sam Brown Healthcare Communications
[email protected]
615.414.8668
646.942.5604
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This news release may contain "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian and United States securities legislation (collectively, "forward-looking statements"). Such forward-looking statements herein include but are not limited to, the Company's current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements, or any other future events or developments constitute forward-looking statements, and the words "may", "will", "would", "should", "could", "expect", "plan", "intend", "trend", "indication", "anticipate", "believe", "estimate", "predict", "likely" or "potential", or the negative or other variations of these words or other comparable words or phrases, are intended to identify forward-looking statements. Forward-looking statements include, without limitation, statements relating to: the expected contributions from our Board Chair; the objectives, planned clinical endpoints, timing, expected rate of enrollment, and timing of data readout and study design of our Phase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury; the future development plans and benefits of NVG-291; the development plans and prospective target indications for NVG-300; and the creation of neuroreparative therapeutics to promote nervous system repair in settings of neurotrauma and neurologic disease.
Forward-looking statements are based on estimates and assumptions made by the company in light of management's experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we believe are appropriate and reasonable in the circumstances. In making forward-looking statements, we have relied on various assumptions, including, but not limited to: our ability to obtain future funding on favourable terms or at all; the accuracy of our financial projections; obtaining positive results in our clinical and other trials; our ability to obtain necessary regulatory approvals; our ability to arrange for the manufacturing of our product candidates and technologies; and general business, market and economic conditions.
Many factors could cause our actual results, level of activity, performance or achievements or future events or developments to differ materially from those expressed or implied by the forward-looking statements, including without limitation, a lack of revenue, insufficient funding, reliance upon key personnel, the uncertainty of the clinical development process, competition, and other factors set forth in the "Risk Factors" section of the company's most recently filed prospectus supplement, short form base shelf prospectus, annual information form, financial statements and management discussion and analysis all of which can be found on NervGen's profile on SEDAR+ at . All clinical development plans are subject to additional funding.
Readers should not place undue reliance on forward-looking statements made in this news release. Furthermore, unless otherwise stated, the forward-looking statements contained in this news release are made as of the date of this news release, and we have no intention and undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
To view the source version of this press release, please visit
FAQ
Who is the new Board Chair of NervGen Pharma (NGENF)?
What are the latest clinical trial results for NervGen's NVG-291?
What is Dr. Adam Rogers' background and experience?
What is NervGen Pharma's main focus and pipeline?
When did Dr. Rogers join NervGen's board?
